Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.63 |
| ▸ | EGFR | P00533 | 9/20 | 0.63 |
| ▸ | ABL1 | P00519 | 4/20 | 0.63 |
| ▸ | LYN | P07948 | 2/20 | 0.63 |
| ▸ | BCR | P11274 | 2/20 | 0.63 |
| ▸ | CSF1R | P07333 | 4/20 | 0.62 |
| ▸ | KIT | P10721 | 4/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943032 | 0.86 | MAP3K7 (0.66) | BRAFEGFRABL1CSF1RKIT | |
| SCHEMBL4698202 | 0.85 | MAPK14 (0.63) | BRAFEGFRABL1LYNBCR | |
| SCHEMBL21943342 | 0.84 | MAP3K7 (0.69) | BRAFEGFRABL1KITSRC | |
| SCHEMBL4697140 | 0.83 | BRAF (0.66) | BRAF | |
| SCHEMBL22024879 | 0.82 | ABL1 (0.71) | BRAFEGFRABL1LYNBCR | |
| SCHEMBL3830316 | 0.81 | KIT (0.64) | BRAFEGFRABL1LYNBCR | |
| SCHEMBL3557483 | 0.81 | ABL1 (0.79) | BRAFEGFRABL1LYNBCR | |
| SCHEMBL22024687 | 0.80 | BRAF (0.76) | BRAFEGFRCSF1RKIT | |
| Hydrochloric Acid SCHEMBL3564245 | 0.80 | ABL1 (0.78) | BRAFEGFRABL1LYNBCR | |
| SCHEMBL4699995 | 0.80 | BRAF (0.68) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | claimed |
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | claimed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | claimed |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | BRAF 42/4885EGFR 34/4885ABL1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.